Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy

INTRODUCTION: Dexamethasone (DEX) is administered for multiple days to prevent chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic chemotherapy (HEC); however, its notorious side effects have been widely reported. Although our multicentre randomised double-blind compara...

Descripción completa

Detalles Bibliográficos
Autores principales: Minatogawa, Hiroko, Izawa, Naoki, Kawaguchi, Takashi, Miyaji, Tempei, Shimomura, Kazuhiro, Kazunori, Honda, Iihara, Hirotoshi, Ohno, Yasushi, Inada, Yusuke, Arioka, Hitoshi, Morita, Hajime, Hida, Naoya, Sugawara, Mitsuhiro, Katada, Chikatoshi, Nawata, Shuichi, Ishida, Hiroo, Tsuboya, Ayako, Tsuda, Takashi, Yamaguchi, Takuhiro, Nakajima, Takako Eguchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747608/
https://www.ncbi.nlm.nih.gov/pubmed/33334838
http://dx.doi.org/10.1136/bmjopen-2020-041737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747608/
https://www.ncbi.nlm.nih.gov/pubmed/33334838
http://dx.doi.org/10.1136/bmjopen-2020-041737

Ejemplares similares